PRESS RELEASES

As usual, there’s a lot of news coming out of the 38th Annual JPMorgan Chase Healthcare Conference. And machine learning’s ability to support the pharmaceutical research and development process is no exception. There have been dozens of presentations on this very topic, and even more companies pitching the promise of artificial intelligence (AI). But, one thing is very clear: More education is needed about how AI can support pharmaceutical research.... read post here.

Like many of you, I am winding down my work week to prepare for the holiday season. As a new decade approaches it is a good time to reflect on the events of the past year.

2019 saw tremendous growth for twoXAR. We launched nine new disease areas, expanding to new disease programs in our focus areas of ophthalmology, immunology & inflammatory, oncology and metabolic. We ended the year with eighteen total diseases in our portfolio, six of which have been out licensed...read post here.

Since co-founding twoXAR five years ago, I have consistently held the same beliefs about AI’s role in drug discovery, and I’ve delivered a consistent message about it. The world’s reaction to my words has evolved, from skepticism to curiosity to full-blown excitement.

Many believe AI is the panacea that will revolutionize the healthcare industry, and dollars are flowing into healthcare AI startups at unprecedented rates as investors make big bets on using the technology to analyze health data, improve efficiency in healthcare delivery, speed drug discovery, and offer new therapies for intractable diseases... read post here.

Five years ago my namefellow, Andrew A. Radin (twoXAR CEO), and I launched twoXAR to apply new technology to discovering medicines for patients with unmet medical needs. Over the years we developed our 3P strategy (platform, process, portfolio) which I am confident is the most efficient, lowest risk, and highest probability path to success in today’s world of drug development.

After careful consideration and planning I’ve decided now is the right time for me to transition to an advisory role at twoXAR. To implement the 3P strategy we’ve built an exceptional team of scientists, engineers, and business professionals that continues to develop and broaden month over month. I am consistently impressed by our team’s expertise, capabilities, and accomplishments — it’s their commitment and dedication that propels forward our mission... read post here.

This week I had the pleasure to sign an R&D collaboration agreement with SK Biopharmaceuticals, our new friends at in South Korea’s Pangyo Techno Valley.

In the last several months, SKBP has achieved several remarkable drug development milestones, including the first FDA approval of an SKBP-discovered drug (Sunosi™, for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea, which has been licensed to Jazz Pharmaceuticals) and FDA acceptance of their NDA submission for cenobamate, an investigational antiepileptic drug. With this recent progress, SKBP is quickly emerging as the leading end-to-end pharmaceutical company in South Korea... read post here.

I'm pleased to announce that we have signed our second partnership deal of 2019; this time in a (undisclosed) neurological disease with Ono Pharmaceutical.

Ono recently celebrated their 300th anniversary of delivering medications to patients in need. When I visited their research headquarters in Osaka, Japan I was impressed by the exposition in their lobby chronicling their rich history. I was reminded of the evolution of the industry and of twoXAR itself... read post here.

twoXAR CEO, Andrew A. Radin presents on the Applications of AI in Drug Discovery

Join twoXAR CEO, Andrew A. Radin and Senior VP of Business Development, Allen Poirson, for an opportunity to meet with MIT-connected startups and hear about their impactful work and technology.

twoXAR CEO, Andrew A. Radin, participates in a panel discussion: Every Healthcare Professionals Dream: AI in Data, Diagnosis and Patient Care.

twoXAR CEO, Andrew A. Radin, participates in a panel discussion on AI and Digital Health.

twoXAR CEO, Andrew A. Radin, participates in a startup lightning talk about twoXAR and discovering pharmaceuticals with AI.

twoXAR VP Discovery, Aaron Daugherty, discusses the applications of AI in Drug Discovery.

twoXAR CEO, Andrew A. Radin, speaks about discovering pharmaceuticals with AI

twoXAR CEO, Andrew A. Radin, speaks about the Applications of AI in Drug Discovery

twoXAR CEO, Andrew A. Radin, speaks with Harry Glorikian of the Moneyball Medicine Podcast.

twoXAR CEO, Andrew A. Radin, is joined by GSK's John Baldoni & Nimbus's Mark Ashwell.

twoXAR CEO, Andrew A. Radin, presents What if new medications could be found in minutes instead of years?

twoXAR CEO, Andrew A. Radin, is joined by Jeff Kindler & Vijay Pande.